Last reviewed · How we verify
Human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Fexinidazole | FEXINIDAZOLE | Sanofi | Nitroimidazole Antimicrobial [EPC] | 2021-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Sanofi · 1 drug in Human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense:
- Human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense treatment updates — RSS
- Human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense treatment updates — Atom
- Human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense treatment updates — JSON
Cite this brief
Drug Landscape (2026). Human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/human-african-trypanosomiasis-hat-due-to-trypanosoma-brucei-gambiense. Accessed 2026-06-10.
Related
- Human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing